You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: Photosonox LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacological chaperones for the treatment of Open-Angle Glaucoma

    SBC: Viewpoint Therapeutics, Inc.            Topic: NEI

    Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: Scribe Biosciences, Inc.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Engineering a unique antibody for patients with RA

    SBC: Abwiz Bio, Inc.            Topic: NIAID

    RA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. HBI-002 to Treat Ulcerative Colitis

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 300

    PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Novel OCT Technology for Detection of Occult Sperm in the Testes inNon- Obstructed Azoospermia.

    SBC: Unasper, Inc.            Topic: NICHD

    Non-obstructive azoospermia (NOA), a lack of sperm in the ejaculate due to defective spermatogenesis, affects as many as 100,000 men in the US, and represents an unmet medical need because many of these men would like to father children, but cannot without surgical intervention. Current therapy for such men is suboptimal, because it relies upon microsurgical testicular sperm extraction (micro-TESE ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government